Effect of statins, angiotensin-converting enzyme inhibitors, and beta blockers on survival in patients >or=65 years of age with heart failure and preserved left ventricular systolic function

The American Journal of Cardiology
Rahman ShahJoanne M Foody

Abstract

About half of all patients with heart failure (HF) have preserved left ventricular systolic function. Statins, angiotensin-converting enzyme inhibitors, and beta blockers have been shown to improve survival in patients with HF and low ejection fraction. However, no large national study has investigated these agents in patients with HF and preserved left ventricular ejection fraction. We evaluated a nationwide sample of 13,533 eligible Medicare beneficiaries aged >or=65 years who were hospitalized with a primary discharge diagnosis of HF and had chart documentation of preserved left ventricular ejection fraction between April 1998 and March 1999 or between July 2000 and June 2001. In Cox proportional hazard model accounting for demographic profile, clinical characteristics, treatments, physician specialty, and hospital characteristics, discharge statin therapy was associated with significant improvements in 1- and 3-year mortality (RR 0.69, 95% confidence interval [CI] 0.61 to 0.78; RR 0.73, 95% CI 0.68 to 0.79, respectively). Irrespective of total cholesterol level or coronary artery disease status, diabetes, hypertension, and age, statin therapy was associated with significant differences in mortality rates. Similarly, angiote...Continue Reading

References

Oct 1, 1996·American Journal of Public Health·K Kenward
May 15, 1998·JAMA : the Journal of the American Medical Association·T A MarciniakS F Jencks
Aug 10, 2000·European Journal of Heart Failure·J G ClelandJ Taylor
Feb 20, 2002·JAMA : the Journal of the American Medical Association·JoAnne Micale FoodyHarlan M Krumholz
Sep 24, 2002·International Journal of Cardiology·Marcelo C ShibataUNKNOWN Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure
Feb 21, 2004·Journal of the American College of Cardiology·Tamara B HorwichGregg C Fonarow
Jul 1, 2004·Circulation Journal : Official Journal of the Japanese Circulation Society·Tsuyoshi ShinozakiUNKNOWN DIAST Investigators
Jan 12, 2005·Archives of Internal Medicine·Joel G RayJack V Tu
Feb 24, 2006·Circulation·JoAnne Micale FoodyHarlan M Krumholz
Sep 12, 2006·European Heart Journal·John G F ClelandUNKNOWN PEP-CHF Investigators
Nov 2, 2006·JAMA : the Journal of the American Medical Association·Alan S GoJerry H Gurwitz

❮ Previous
Next ❯

Citations

Nov 26, 2009·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Abhimanyu BeriSnigdha B Mahajan
Jan 1, 2010·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Mario Marzilli
Jul 1, 2014·Heart Failure Clinics·Jose Nativi-NicolauJames C Fang
Sep 12, 2013·Pharmacology & Therapeutics·Dimitris TousoulisChristodoulos Stefanadis
Jun 9, 2014·Medicina clínica·Ricardo Gómez-HuelgasJosé María Lobos
Feb 12, 2014·The American Journal of Cardiology·Gang LiuXiao-Hong Huang
Sep 17, 2009·Research in Social & Administrative Pharmacy : RSAP·Tonya CrawfordRafia S Rasu
Apr 25, 2008·Heart Failure Clinics·Ragavendra R Baliga, James B Young
Aug 30, 2008·British Journal of Clinical Pharmacology·Sylvie PerreaultMichel White
Mar 7, 2014·Clinical Science·Clare A McKinneyStuart A Nicklin
Mar 15, 2012·Annals of Medicine·Kannayiram AlagiakrishnanWilbert S Aronow
Jul 19, 2014·Heart Failure Reviews·Chirag BavishiFranz H Messerli
Mar 10, 2009·The American Journal of Cardiology·Faramarz TehraniErnst R Schwarz
May 10, 2018·Journal of Cellular Physiology·Hamid Reza NejabatiMohammad Nouri
Feb 4, 2010·Clinical Cardiology·Faramarz TehraniErnst R Schwarz
Mar 18, 2010·Nature Reviews. Cardiology·W H Wilson Tang, Gary S Francis
Feb 13, 2009·Expert Review of Cardiovascular Therapy·Ana C Alba, Diego H Delgado
Oct 30, 2012·Journal of Cardiopulmonary Rehabilitation and Prevention·Armando SturchioSoccorso Capomolla
Sep 11, 2019·Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis·Hari DukkaMaarten W Taal
May 12, 2020·The Korean Journal of Internal Medicine·Mi-Na Kim, Seong-Mi Park
Aug 8, 2018·European Heart Journal·Christopher J RushJohn J V McMurray
Mar 20, 2016·American Journal of Physiology. Heart and Circulatory Physiology·Patrícia G RodriguesInês Falcão-Pires
Nov 13, 2018·Circulation Journal : Official Journal of the Japanese Circulation Society·Kyohei MarumeToshihisa Anzai
Nov 22, 2017·Journal of cardiology·Jaelim ChoUNKNOWN Other Korea Acute Myocardial Infarction Registry (KAMIR) and Korea Working Group on Myocardial Infarction (KorMI) Investigat

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.